Regulatory guidance versus literature data [Power / Sample Size]

posted by mahmoud-teaima  – 2017-05-23 14:31 (3317 d 09:53 ago) – Posting: # 17392
Views: 6,415

Salam Helmut,
Thank you for the detailed, evidence-proofed explanation.

The problem here is that literature data archiving the PKs and output of previous BE studies on simvastatin show border ISV with CV around 30% (29% - 33%).

On the contrary, till the moment, the FDA guidance for BE study on Simvastatin doesn't involve reference scaling
https://www.fda.gov/downloads/Drugs/.../Guidances/ucm086171.pdf
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm089636.pdf

So, the straightforward question is:
Does the BE study of Simvastatin involve reference scaling due the border ISV of simvastatin derived from literature though the regulator doesn't imply that?

Greetings.

Mahmoud Teaima, PhD.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
128 visitors (0 registered, 128 guests [including 29 identified bots]).
Forum time: 00:25 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5